113 related articles for article (PubMed ID: 19621008)
1. A truncated erythropoietin receptor EPOR-T is associated with hypertension susceptibility.
Carruthers SG
Clin Pharmacol Ther; 2009 Aug; 86(2):134-6. PubMed ID: 19621008
[TBL] [Abstract][Full Text] [Related]
2. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients.
Ioka T; Tsuruoka S; Ito C; Iwaguro H; Asahara T; Fujimura A; Kusano E
Clin Pharmacol Ther; 2009 Aug; 86(2):154-9. PubMed ID: 19458615
[TBL] [Abstract][Full Text] [Related]
3. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
Krapf R; Hulter HN
Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
[TBL] [Abstract][Full Text] [Related]
4. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
Mannello F; Tonti GA
Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells.
Beleslin-Cokic BB; Cokic VP; Yu X; Weksler BB; Schechter AN; Noguchi CT
Blood; 2004 Oct; 104(7):2073-80. PubMed ID: 15205261
[TBL] [Abstract][Full Text] [Related]
7. [The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: beyond anaemia].
Ortega LM; Contreras G
Nefrologia; 2009; 29(4):288-94. PubMed ID: 19668298
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin and arterial hypertension.
Luft FC
Clin Nephrol; 2000 Feb; 53(1 Suppl):S61-4. PubMed ID: 10746808
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
Veng-Pedersen P; Chapel S; Al-Huniti NH; Schmidt RL; Sedars EM; Hohl RJ; Widness JA
Biopharm Drug Dispos; 2004 May; 25(4):149-56. PubMed ID: 15108217
[TBL] [Abstract][Full Text] [Related]
10. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity.
Banerjee D; Rodriguez M; Nag M; Adamson JW
Kidney Int; 2000 May; 57(5):1895-904. PubMed ID: 10792608
[TBL] [Abstract][Full Text] [Related]
11. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.
Sinclair AM; Coxon A; McCaffery I; Kaufman S; Paweletz K; Liu L; Busse L; Swift S; Elliott S; Begley CG
Blood; 2010 May; 115(21):4264-72. PubMed ID: 20124513
[TBL] [Abstract][Full Text] [Related]
12. The FDA black box for EPO: what should nephrologists do?
Singh AK
Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
[No Abstract] [Full Text] [Related]
13. [The treatment of chemotherapy-induced anemia in lung cancer patients].
Gálffy G
Magy Onkol; 2013 Mar; 57(1):39-49. PubMed ID: 23573521
[TBL] [Abstract][Full Text] [Related]
14. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of erythropoietin receptor in human pterygial tissues.
Kase S; Osaki M; Jin XH; Ohgami K; Yoshida K; Saito W; Takahashi S; Nakanishi K; Ito H; Ohno S
Int J Mol Med; 2007 Nov; 20(5):699-702. PubMed ID: 17912463
[TBL] [Abstract][Full Text] [Related]
16. The hyperresponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum.
Damen JE; Krosl J; Morrison D; Pelech S; Krystal G
Blood; 1998 Jul; 92(2):425-33. PubMed ID: 9657741
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin and the endothelium - a promising link?
Fliser D; Bahlmann FH
Eur J Clin Invest; 2008 Jul; 38(7):457-61. PubMed ID: 18505404
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.
Arcasoy MO
Clin Cancer Res; 2008 Aug; 14(15):4685-90. PubMed ID: 18676735
[TBL] [Abstract][Full Text] [Related]
19. Relationships of P53 and Bak with EPO and EPOR in human colorectal cancer.
Baltaziak M; Koda M; Wincewicz A; Sulkowska M; Kanczuga-Koda L; Sulkowski S
Anticancer Res; 2009 Oct; 29(10):4151-6. PubMed ID: 19846965
[TBL] [Abstract][Full Text] [Related]
20. The erythropoietin receptor in normal and cancer tissues.
Jelkmann W; Bohlius J; Hallek M; Sytkowski AJ
Crit Rev Oncol Hematol; 2008 Jul; 67(1):39-61. PubMed ID: 18434185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
